Treats inflammatory papules and pustules of rosacea. ANDA 217128, held by Zydus Lifesciences. Metronidazole.
As of Nov 21, 2026, ANDA 217128 (Metronidazole), held by Zydus Lifesciences, was first approved by FDA on Apr 21, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Metronidazole topical cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 21, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metronidazole0.75% · cream;topical | Metronidazole | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters